-
2024-510581-17-00
4
2024-11-05
Adult subjects with New York Heart Association (NYHA) Class III conges
-
2023-509300-14-00
5
2024-10-31
Severe hypertriglyceridemia (SHTG)
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
-
2022-502168-19-00
4
2024-10-22
chronic graft-versus-host disease
-
2024-511038-11-00
4
2024-09-24
advanced prostate cancer
-
2023-507851-31-00
5
2024-09-23
Immunoglobulin A Nephropathy (IgAN)
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2024-510965-41-00
5
2024-09-03
Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-505423-31-00
5
2024-08-08
advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
-
2023-505746-25-00
4
2024-07-16
Cold agglutinin disease
-
2022-502661-23-00
7
2024-06-11
Relapsed/refractory B-cell non-Hodgkin lymphoma
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.
-
2023-507685-10-00
5
2024-05-30
High-Risk Non-muscle-invasive Bladder Cancer
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2023-508166-15-00
6
2024-04-29
Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
-
2023-507333-17-00
5
2024-04-15
HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
-
2023-504416-16-00
5
2024-04-11
Psychosis Associated with Alzheimer’s Disease
-
2023-504541-31-00
5
2024-03-06
Myelodysplastic syndrome
-
2023-503575-21-00
5
2024-01-23
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2022-502669-14-00
5
2023-12-18
Small cell lung cancer (SCLC)
-
2022-501396-62-00
5
2023-12-12
Relapsed Refractory Multiple Myeloma
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co